Keri RA - Search Results

1

Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer.

Milliken EL, Lozada KL, Johnson E, Landis MD, Seachrist DD, Whitten I, Sutton AL, Abdul-Karim FW, Keri RA. Milliken EL, et al. Among authors: keri ra. Oncogene. 2008 Mar 13;27(12):1759-66. doi: 10.1038/sj.onc.1210815. Epub 2007 Sep 24. Oncogene. 2008. PMID: 17891171 Free PMC article.

2

Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition.

Keri RA, Lozada KL, Abdul-Karim FW, Nadeau JH, Nilson JH. Keri RA, et al. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):383-7. doi: 10.1073/pnas.97.1.383. Proc Natl Acad Sci U S A. 2000. PMID: 10618427 Free PMC article.

3

Chronic hypersecretion of luteinizing hormone in transgenic mice disrupts both ovarian and pituitary function, with some effects modified by the genetic background.

Nilson JH, Abbud RA, Keri RA, Quirk CC. Nilson JH, et al. Among authors: keri ra. Recent Prog Horm Res. 2000;55:69-89; discussion 89-91. Recent Prog Horm Res. 2000. PMID: 11036934 Review.

4

A single Pitx1 binding site is essential for activity of the LHbeta promoter in transgenic mice.

Quirk CC, Lozada KL, Keri RA, Nilson JH. Quirk CC, et al. Among authors: keri ra. Mol Endocrinol. 2001 May;15(5):734-46. doi: 10.1210/mend.15.5.0628. Mol Endocrinol. 2001. PMID: 11328855

5

Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice.

Milliken EL, Ameduri RK, Landis MD, Behrooz A, Abdul-Karim FW, Keri RA. Milliken EL, et al. Among authors: keri ra. Endocrinology. 2002 Sep;143(9):3671-80. doi: 10.1210/en.2002-220228. Endocrinology. 2002. PMID: 12193583

6

Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology.

Mann RJ, Keri RA, Nilson JH. Mann RJ, et al. Among authors: keri ra. Recent Prog Horm Res. 2003;58:343-75. doi: 10.1210/rp.58.1.343. Recent Prog Horm Res. 2003. PMID: 12795427 Review.

7

Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.

Landis MD, Seachrist DD, Montañez-Wiscovich ME, Danielpour D, Keri RA. Landis MD, et al. Among authors: keri ra. Oncogene. 2005 Aug 4;24(33):5173-90. doi: 10.1038/sj.onc.1208712. Oncogene. 2005. PMID: 15897883 Free PMC article.

8

EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.

Milliken EL, Zhang X, Flask C, Duerk JL, MacDonald PN, Keri RA. Milliken EL, et al. Among authors: keri ra. Cancer Lett. 2005 Nov 18;229(2):205-15. doi: 10.1016/j.canlet.2005.06.044. Epub 2005 Aug 22. Cancer Lett. 2005. PMID: 16115727 Free PMC article.

9

Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA. Landis MD, et al. Among authors: keri ra. Oncogene. 2006 Jun 1;25(23):3325-34. doi: 10.1038/sj.onc.1209365. Epub 2006 Jan 23. Oncogene. 2006. PMID: 16434967 Free PMC article.

10

Increases in luteinizing hormone are associated with declines in cognitive performance.

Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, Perry G, Keri RA, Smith MA. Casadesus G, et al. Among authors: keri ra. Mol Cell Endocrinol. 2007 Apr 15;269(1-2):107-11. doi: 10.1016/j.mce.2006.06.013. Epub 2007 Feb 6. Mol Cell Endocrinol. 2007. PMID: 17376589

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters